Investor Presentaiton slide image

Investor Presentaiton

Company overview Financial performance Oncology Financial review 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Immunology Ophthalmology Neuroscience Respiratory Disease Cardio-Renal Global Health Biosimilars Immunology 65 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine
View entire presentation